Efficacy of brigatinib in pretreated ALK+ patients with advanced non-small cell lung cancer: A retrospective multicenter real-world study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Sep 2021 Primary endpoint (Investigator-assessed progression-free survival) has been met, according to Results presented at the 46th European Society for Medical Oncology Congress.
21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
21 Sep 2020 Results of an analysis assessing the efficacy of brigatinib in a cohort of heavily pretreated for ALK-positive advanced NSCLC patients, presented at the 45th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com